.jpg)
Listen: Remdesivir’s controversial cost, early vaccine promise, and AI at the end of life
What’s a fair price for remdesivir? How do we know whether vaccines work? And does AI have a place in end-of-life care?
We discuss all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, we dig into the long-awaited price for Gilead Sciences’ Covid-19 treatment and break down the disparate reactions from lawmakers, activists, and Wall Street analysts. Then, STAT’s Matthew Herper joins us to discuss some of the first detailed data on a potential vaccine for the novel coronavirus. Finally, we talk about a new use for AI: nudging clinicians to broach delicate conversations with patients about their end-of-life goals and wishes.
